GLP-1s Can Potentially Cut Cirrhosis, Related Complications in MASLD: Study - BioSpace
GLP-1 receptor agonists significantly reduce cirrhosis progression and complications in patients with metabolic dysfunction-associated steatotic liver disease, according to a study in JAMA Internal Medicine. The study, based on over 16,000 patients, found a 14% reduction in cirrhosis risk and lower risks of complications and mortality. These findings suggest potential preventive treatment for cirrhosis in diabetes and MASLD patients.
Reference News
GLP-1 receptor agonists significantly reduce cirrhosis progression and complications in patients with metabolic dysfunction-associated steatotic liver disease, according to a study in JAMA Internal Medicine. The study, based on over 16,000 patients, found a 14% reduction in cirrhosis risk and lower risks of complications and mortality. These findings suggest potential preventive treatment for cirrhosis in diabetes and MASLD patients.